Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
NuLiv Science USA, Inc. manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area. There is currently 1 pending office action for the company. This action is assigned to 1 distinct examiner and 1 distinct art unit, reflecting a very focused prosecution environment. Such a concentration suggests that the company's intellectual property strategy is currently centered on a specific technical niche within the broader Biotechnology & Pharmaceuticals field.
The busiest examiner for this portfolio is HOFFMAN, SUSAN COE, who is managing 1 pending office action. Because the company has only 1 pending office action, HOFFMAN, SUSAN COE is responsible for the 1 pending office action currently active. The outcome of this biotechnology portfolio is currently subject to the specific examination standards of this 1 distinct examiner. For a practitioner, this implies that understanding the historical allowance rates and preferences of HOFFMAN, SUSAN COE is critical for predicting the success of the 1 pending office action.
The presence of only the 1 distinct art unit further reinforces the specialized nature of the company's current filings. With the pending office action as the only active matter, the company's immediate legal focus is streamlined. This lack of diversity in examiners and art units simplifies the management of the portfolio but also increases the impact of any single decision made by the assigned examiner within the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOFFMAN, SUSAN COE | 1 | 54.2% | +25.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18239287 | COMPOSITION OF BOTANICAL EXTRACTS FOR SLEEP AND MOOD SUPPORT | HOFFMAN, SUSAN COE | 77d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18239287 | COMPOSITION OF BOTANICAL EXTRACTS FOR SLEEP AND MOOD SUPPORT | HOFFMAN, SUSAN COE | 77d overdue |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18239287 | COMPOSITION OF BOTANICAL EXTRACTS FOR SLEEP AND MOOD SUPPORT | HOFFMAN, SUSAN COE | 1655 | §101§102§103§112 | Non-Final OA | 77d overdue | Pending | Aug 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNuLiv Science USA, Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Susan Coe Hoffman has the most, with 1 of NuLiv Science USA, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.